Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Time Course of Drug Effect01:14

Time Course of Drug Effect

3.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
3.0K
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

331
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
331
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

958
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
958
Drug Concentration Versus Time Correlation01:15

Drug Concentration Versus Time Correlation

3.1K
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
3.1K
Drug Concentrations: Measurements01:23

Drug Concentrations: Measurements

1.7K
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
1.7K
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

983
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
983

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Species-level virome profiling reveals compositional differences in the gut prokaryotic DNA virome of people with HIV-1 on antiretroviral therapy.

Gut microbes reports·2026
Same author

Letter to the editor: When do rare events become expected in HIV drug resistance?

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2026
Same author

HIV-1 Sub-subtype A6 Remains Susceptible to Second-Generation Integrase Inhibitors With Limited Emergence of Resistance in Vitro.

Open forum infectious diseases·2026
Same author

Increased in-hospital mortality in immunocompromised individuals hospitalized with COVID-19 during the global pandemic, a multinational cohort study in the EuCARE project.

The Journal of infectious diseases·2026
Same author

HIV-1 viral load and reservoir size remain stable following SARS-CoV-2 mRNA vaccination in people with HIV.

HIV medicine·2026
Same author

Linking gut microbiome to HIV-1 reservoir size in people living with HIV.

Gut pathogens·2026

Related Experiment Video

Updated: Apr 20, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

10.5K

Time on drug analysis based on real life data.

Eugen Schülter1, Rolf Kaiser1, Maurizio Zazzi2

  • 1Institute of Virology, University of Cologne, Cologne, Germany.

Journal of the International AIDS Society
|November 15, 2014
PubMed
Summary

Lifelong HIV-1 treatment requires combination antiretroviral therapy (cART), but drug changes are frequent. Newer HIV drugs show longer effectiveness and tolerability compared to older ones, suggesting improved long-term treatment outcomes.

More Related Videos

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

8.4K
Rapid High-throughput Species Identification of Botanical Material Using Direct Analysis in Real Time High Resolution Mass Spectrometry
11:14

Rapid High-throughput Species Identification of Botanical Material Using Direct Analysis in Real Time High Resolution Mass Spectrometry

Published on: October 2, 2016

12.3K

Related Experiment Videos

Last Updated: Apr 20, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

10.5K
Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

8.4K
Rapid High-throughput Species Identification of Botanical Material Using Direct Analysis in Real Time High Resolution Mass Spectrometry
11:14

Rapid High-throughput Species Identification of Botanical Material Using Direct Analysis in Real Time High Resolution Mass Spectrometry

Published on: October 2, 2016

12.3K

Area of Science:

  • Virology
  • Pharmacology
  • Public Health

Background:

  • HIV-1 treatment has advanced, but lifelong antiretroviral therapy (ART) remains necessary.
  • Challenges in ART include drug resistance, side effects, and interactions, impacting long-term regimen stability.
  • Average drug duration in combination antiretroviral therapy (cART) can indicate treatment effectiveness and tolerability.

Purpose of the Study:

  • To evaluate the duration of individual drugs within cART regimens for HIV-1 infected patients.
  • To assess drug discontinuation rates and identify potential differences in effectiveness and tolerability among antiretroviral drugs.
  • To inform long-term HIV treatment strategies by analyzing drug performance data.

Main Methods:

  • Extracted therapy episodes from the EuResist database (Oct 2006-Oct 2012).
  • Included patients with at least two years of continuous monitoring and analyzed drugs with at least 100 cases.
  • Ignored drug interruptions shorter than one month; calculated average drug intake duration and discontinuation rates.

Main Results:

  • Analyzed 38,153 cARTs from 11,499 patients; average drug intake was 18.7 months.
  • Specific drug durations varied, with some newer drugs like FTC (23.2 months) and TDF (23.0 months) showing longer use.
  • Two-year discontinuation rates were high overall (48.8%), with significant differences across drug classes (e.g., PIs at 55.4%).

Conclusions:

  • High frequency of therapy changes in cART necessitates anticipating numerous regimen modifications over time.
  • Observed differences in drug durations suggest potential advantages of newer antiretroviral agents over older ones.
  • Further analysis is needed to explore confounding factors influencing drug duration and discontinuation.